@article{oai:repo.qst.go.jp:00085191,
 author = {Wang, Duo and Zhou, Jun and Fang, Weimin and Huang, Cuiqing and Chen, Zerong and Fan, Meng and Zhang, Ming-Rong and Xiao, Zeyu and Kuan, Hu and Luo, Liangping and Zhang, Ming-Rong and Kuan, Hu},
 journal = {Bioactive Materials},
 month = {Nov},
 note = {Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as Erlotinib, have demonstrated 
remarkable efficacy in the treatment of non-small cell lung cancer (NSCLC) patients with mutated EGFR. 
However, the efficacy of EGFR-TKIs in wild-type (wt) EGFR tumours has been shown to be marginal. Methods 
that can sensitize Erlotinib to EGFR wild-type NSCLC remain rare. Herein, we developed a multifunctional 
superparamagnetic nanotheranostic agent as a novel strategy to potentiate Erlotinib to EGFR-wt NSCLCs. Our 
results demonstrate that the nanoparticles can co-escort Erlotinib and a vascular epithermal growth factor 
(VEGF) inhibitor, Bevacizumab (Bev), to EGFR-wt tumours. The nanotheranostic agent exhibits remarkable effects as an inhibitor of EGFR-wt tumour growth. Moreover, Bev normalizes the tumour embedded vessels, further 
promoting the therapeutic efficacy of Erlotinib. In addition, the tumour engagement of the nanoparticles and the 
vascular normalization could be tracked by magnetic resonance imaging (MRI). Collectively, our study, for the 
first time, demonstrated that elaborated nanoparticles could be employed as a robust tool to potentiate Erlotinib 
to EGFR-wt NSCLC, paving the way for imaging-guided nanotheranostics for refractory NSCLCs expressing EGFR 
wild-type genes.},
 pages = {312--323},
 title = {A multifunctional nanotheranostic agent potentiates erlotinib to EGFR  wild-type non-small cell lung cancer},
 volume = {13},
 year = {2021}
}